Inhibrx Other Liab vs Current Deferred Revenue Analysis

INBX Stock

USD 21.60 0.32 1.46%

Trend analysis of Inhibrx Biosciences, balance sheet accounts such as Other Current Liabilities of 15.2 M or Total Current Liabilities of 28 M provides information on Inhibrx Biosciences,'s total assets, liabilities, and equity, which is the actual value of Inhibrx Biosciences, to its prevalent stockholders. By breaking down trends over time using Inhibrx Biosciences, balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Total Assets Non Current Assets Total

Build AI portfolio with Inhibrx Stock

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibrx Biosciences,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Inhibrx Stock please use our How to Invest in Inhibrx Biosciences, guide.

About Inhibrx Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Inhibrx Biosciences, at a specified time, usually calculated after every quarter, six months, or one year. Inhibrx Biosciences, Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Inhibrx Biosciences, and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Inhibrx currently owns. An asset can also be divided into two categories, current and non-current.

Inhibrx Biosciences, Balance Sheet Chart

At this time, Inhibrx Biosciences,'s Total Stockholder Equity is fairly stable compared to the past year. Common Stock Shares Outstanding is likely to rise to about 26.1 M in 2025, whereas Total Assets are likely to drop slightly above 140.4 M in 2025.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Total Assets

Total assets refers to the total amount of Inhibrx Biosciences, assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Inhibrx Biosciences, books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Inhibrx Biosciences, balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Inhibrx Biosciences, are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Inhibrx Biosciences,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Inhibrx Biosciences, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibrx Biosciences,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Inhibrx Stock please use our How to Invest in Inhibrx Biosciences, guide.At this time, Inhibrx Biosciences,'s Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to 2,133 in 2025, whereas Issuance Of Capital Stock is likely to drop 0.00 in 2025.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	131.3M	219.8M	331.6M	348.2M
Cost Of Revenue	2.8M	1.2M	2.3M	2.2M

Total Operating Expenses Cost Of Revenue

Inhibrx Biosciences, fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Total Liab	Total Current Assets	Short Term Debt	Current Deferred Revenue	Net Receivables	Inventory	Other Stockholder Equity	Non Currrent Assets Other	Common Stock	Capital Lease Obligations	Net Invested Capital
Total Assets		0.83	0.91	0.87	0.67	0.7	-0.74	-0.92	0.65	1.0	0.75	1.0	0.11	0.75	0.27	0.83	1.0	-0.51	-0.58	-0.36	-0.17	0.98	0.46	0.34	-0.06	0.66
Short Long Term Debt Total	0.83		0.68	0.62	0.19	0.35	-0.24	-0.93	0.29	0.84	0.38	0.84	0.58	0.96	0.07	0.95	0.84	-0.07	-0.33	-0.2	0.02	0.84	0.04	0.66	-0.5	0.42
Other Current Liab	0.91	0.68		0.96	0.64	0.73	-0.73	-0.86	0.67	0.89	0.8	0.89	-0.02	0.63	0.22	0.74	0.9	-0.45	-0.54	-0.27	-0.11	0.91	0.55	0.18	0.02	0.87
Total Current Liabilities	0.87	0.62	0.96		0.6	0.85	-0.73	-0.83	0.81	0.85	0.88	0.85	-0.12	0.62	0.35	0.74	0.86	-0.48	-0.41	-0.29	-0.24	0.87	0.47	0.15	0.03	0.81
Total Stockholder Equity	0.67	0.19	0.64	0.6		0.57	-0.97	-0.4	0.61	0.67	0.64	0.67	-0.42	0.03	0.33	0.17	0.66	-0.8	-0.71	-0.3	-0.27	0.65	0.78	-0.19	0.47	0.57
Property Plant And Equipment Net	0.7	0.35	0.73	0.85	0.57		-0.72	-0.56	0.85	0.66	0.97	0.66	-0.34	0.41	0.44	0.53	0.67	-0.69	-0.09	-0.43	-0.37	0.64	0.38	-0.1	0.31	0.51
Net Debt	-0.74	-0.24	-0.73	-0.73	-0.97	-0.72		0.47	-0.74	-0.72	-0.79	-0.72	0.48	-0.14	-0.37	-0.29	-0.72	0.79	0.65	0.39	0.3	-0.69	-0.78	0.21	-0.48	-0.63
Retained Earnings	-0.92	-0.93	-0.86	-0.83	-0.4	-0.56	0.47		-0.54	-0.92	-0.58	-0.92	-0.39	-0.88	-0.18	-0.93	-0.93	0.26	0.43	0.11	0.07	-0.96	-0.22	-0.56	0.4	-0.67
Accounts Payable	0.65	0.29	0.67	0.81	0.61	0.85	-0.74	-0.54		0.63	0.83	0.63	-0.4	0.31	0.66	0.44	0.63	-0.68	-0.3	-0.15	-0.59	0.62	0.29	0.12	0.17	0.45
Cash	1.0	0.84	0.89	0.85	0.67	0.66	-0.72	-0.92	0.63		0.71	1.0	0.14	0.76	0.27	0.83	1.0	-0.5	-0.6	-0.35	-0.17	0.98	0.45	0.36	-0.08	0.64
Non Current Assets Total	0.75	0.38	0.8	0.88	0.64	0.97	-0.79	-0.58	0.83	0.71		0.71	-0.39	0.42	0.33	0.55	0.72	-0.67	-0.25	-0.47	-0.24	0.68	0.52	-0.15	0.4	0.59
Cash And Short Term Investments	1.0	0.84	0.89	0.85	0.67	0.66	-0.72	-0.92	0.63	1.0	0.71		0.14	0.76	0.27	0.83	1.0	-0.5	-0.6	-0.35	-0.17	0.98	0.45	0.36	-0.08	0.64
Common Stock Shares Outstanding	0.11	0.58	-0.02	-0.12	-0.42	-0.34	0.48	-0.39	-0.4	0.14	-0.39	0.14		0.53	-0.27	0.43	0.14	0.37	0.15	0.34	0.3	0.21	-0.46	0.68	-0.84	-0.04
Non Current Liabilities Total	0.75	0.96	0.63	0.62	0.03	0.41	-0.14	-0.88	0.31	0.76	0.42	0.76	0.53		0.03	0.98	0.76	0.05	-0.16	-0.25	0.05	0.74	-0.04	0.59	-0.51	0.36
Other Current Assets	0.27	0.07	0.22	0.35	0.33	0.44	-0.37	-0.18	0.66	0.27	0.33	0.27	-0.27	0.03		0.1	0.26	-0.54	0.04	-0.03	-0.99	0.26	-0.22	0.3	-0.06	0.0
Total Liab	0.83	0.95	0.74	0.74	0.17	0.53	-0.29	-0.93	0.44	0.83	0.55	0.83	0.43	0.98	0.1		0.84	-0.07	-0.23	-0.29	0.0	0.82	0.08	0.53	-0.42	0.49
Total Current Assets	1.0	0.84	0.9	0.86	0.66	0.67	-0.72	-0.93	0.63	1.0	0.72	1.0	0.14	0.76	0.26	0.84		-0.49	-0.59	-0.34	-0.16	0.98	0.45	0.36	-0.09	0.65
Short Term Debt	-0.51	-0.07	-0.45	-0.48	-0.8	-0.69	0.79	0.26	-0.68	-0.5	-0.67	-0.5	0.37	0.05	-0.54	-0.07	-0.49		0.28	0.15	0.51	-0.49	-0.38	0.08	-0.46	-0.25
Current Deferred Revenue	-0.58	-0.33	-0.54	-0.41	-0.71	-0.09	0.65	0.43	-0.3	-0.6	-0.25	-0.6	0.15	-0.16	0.04	-0.23	-0.59	0.28		0.05	-0.09	-0.57	-0.7	-0.1	-0.17	-0.53
Net Receivables	-0.36	-0.2	-0.27	-0.29	-0.3	-0.43	0.39	0.11	-0.15	-0.35	-0.47	-0.35	0.34	-0.25	-0.03	-0.29	-0.34	0.15	0.05		0.03	-0.19	-0.42	0.44	-0.48	-0.08
Inventory	-0.17	0.02	-0.11	-0.24	-0.27	-0.37	0.3	0.07	-0.59	-0.17	-0.24	-0.17	0.3	0.05	-0.99	0.0	-0.16	0.51	-0.09	0.03		-0.15	0.27	-0.26	0.03	0.1
Other Stockholder Equity	0.98	0.84	0.91	0.87	0.65	0.64	-0.69	-0.96	0.62	0.98	0.68	0.98	0.21	0.74	0.26	0.82	0.98	-0.49	-0.57	-0.19	-0.15		0.42	0.41	-0.19	0.72
Non Currrent Assets Other	0.46	0.04	0.55	0.47	0.78	0.38	-0.78	-0.22	0.29	0.45	0.52	0.45	-0.46	-0.04	-0.22	0.08	0.45	-0.38	-0.7	-0.42	0.27	0.42		-0.56	0.6	0.67
Common Stock	0.34	0.66	0.18	0.15	-0.19	-0.1	0.21	-0.56	0.12	0.36	-0.15	0.36	0.68	0.59	0.3	0.53	0.36	0.08	-0.1	0.44	-0.26	0.41	-0.56		-0.8	-0.05
Capital Lease Obligations	-0.06	-0.5	0.02	0.03	0.47	0.31	-0.48	0.4	0.17	-0.08	0.4	-0.08	-0.84	-0.51	-0.06	-0.42	-0.09	-0.46	-0.17	-0.48	0.03	-0.19	0.6	-0.8		0.01
Net Invested Capital	0.66	0.42	0.87	0.81	0.57	0.51	-0.63	-0.67	0.45	0.64	0.59	0.64	-0.04	0.36	0.0	0.49	0.65	-0.25	-0.53	-0.08	0.1	0.72	0.67	-0.05	0.01

Click cells to compare fundamentals

Inhibrx Biosciences, Account Relationship Matchups

Inhibrx Biosciences, fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	143.7M	150.5M	290.9M	307.9M	180.8M	140.4M
Short Long Term Debt Total	37.5M	70.5M	202.1M	210.1M	8.0M	7.6M
Other Current Liab	13.4M	9.6M	19.3M	43.9M	29.9M	15.2M
Total Current Liabilities	31.4M	22.5M	27.6M	56.3M	40.7M	28.0M
Total Stockholder Equity	75.5M	52.4M	58.1M	43.5M	133.6M	140.3M
Property Plant And Equipment Net	11.3M	9.5M	7.2M	9.4M	13.5M	8.2M
Net Debt	(91.2M)	(60.8M)	(71.8M)	(67.8M)	(144.5M)	(137.3M)
Retained Earnings	(145.4M)	(227.1M)	(372.4M)	(613.7M)	(106.1M)	(111.4M)
Accounts Payable	13.5M	9.1M	4.3M	8.3M	9.2M	6.7M
Cash	128.7M	131.3M	273.9M	277.9M	152.6M	123.6M
Non Current Assets Total	11.6M	11.3M	10.4M	12.5M	20.4M	10.3M
Cash And Short Term Investments	128.7M	131.3M	273.9M	277.9M	152.6M	123.6M
Common Stock Shares Outstanding	25.3M	38.0M	40.1M	47.1M	14.5M	26.1M
Liabilities And Stockholders Equity	143.7M	150.5M	290.9M	307.9M	180.8M	140.4M
Non Current Liabilities Total	36.9M	75.6M	205.2M	208.1M	6.5M	6.1M
Other Current Assets	132.2M	7.8M	5.5M	16.7M	6.9M	6.6M
Total Liab	68.3M	98.1M	232.8M	264.4M	47.2M	44.8M
Total Current Assets	132.2M	139.1M	280.5M	295.4M	160.4M	130.1M
Short Term Debt	1.5M	1.7M	3.7M	4.1M	1.6M	2.9M
Current Deferred Revenue	7.9M	3.1M	2.0M	166K	149.4K	141.9K
Net Receivables	615K	878K	257K	778K	420K	477.2K
Inventory	3.2M	(129.3M)	(878K)	(257K)	(231.3K)	(242.9K)
Other Stockholder Equity	220.8M	279.5M	430.4M	657.2M	239.7M	236.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

USOI	Credit Suisse X Links
ULTY	Tidal Trust II
CONY	YieldMax N Option

Additional Tools for Inhibrx Stock Analysis

When running Inhibrx Biosciences,'s price analysis, check to measure Inhibrx Biosciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx Biosciences, is operating at the current time. Most of Inhibrx Biosciences,'s value examination focuses on studying past and present price action to predict the probability of Inhibrx Biosciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx Biosciences,'s price. Additionally, you may evaluate how the addition of Inhibrx Biosciences, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Inhibrx Other Liab vs Current Deferred Revenue Analysis

About Inhibrx Balance Sheet Analysis

Inhibrx Biosciences, Balance Sheet Chart

Total Assets

Total Current Liabilities

Inhibrx Biosciences, fundamental ratios Correlations

Inhibrx Biosciences, Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Inhibrx Biosciences, fundamental ratios Accounts

Also Currently Popular

Additional Tools for Inhibrx Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments

Inventory	- 0.99	Other Current Assets
Net Debt	- 0.97	Total Stockholder Equity
Other Stockholder Equity	- 0.96	Retained Earnings
Total Current Assets	- 0.93	Retained Earnings
Total Liab	- 0.93	Retained Earnings
Retained Earnings	- 0.93	Short Long Term Debt Total